Pharming Group (PHGUF) Stock Price, News & Analysis

Company Overview

Pharming Group NV is a biotechnology company headquartered in Leiden, the Netherlands, specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988, the company leverages its proprietary technology platform to produce recombinant human proteins in transgenic animals, aiming to address conditions with high unmet medical need. Pharming’s flagship product is RUCONEST, a recombinant C1 esterase inhibitor indicated for the treatment and prevention of hereditary angioedema (HAE) attacks.

RUCONEST is marketed in North America, Europe and several other territories through a combination of direct sales and strategic partnerships. In addition to its core HAE franchise, Pharming is advancing a pipeline of next-generation enzyme replacement therapies and prophylactic biologics targeting rare genetic disorders and acute respiratory conditions. The company has preclinical and clinical stage programs focused on novel protein candidates designed to restore deficient or dysfunctional enzymes in patient populations.

Pharming Group serves patients and healthcare providers across the United States, the European Union and other global markets. The company maintains manufacturing operations in the Netherlands, ensuring compliance with stringent quality standards for biologic production. Pharming’s management team comprises experienced professionals in biotechnology research, regulatory affairs and commercial strategy, reinforcing its commitment to expand access to life-saving therapies for rare disease communities around the world.

Key Stats

• Today's Range: $1.15 to $1.15
• 50-Day Range: $0.91 to $1.19
• 52-Week Range: $0.75 to $1.19
• Volume: N/A
• Average Volume: 9 shs
• Market Capitalization: $771.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PHGUF Stock Analysis - Frequently Asked Questions

How have PHGUF shares performed this year?

Pharming Group's stock was trading at $0.9815 on January 1st, 2025. Since then, PHGUF shares have increased by 17.2% and is now trading at $1.15.

How were Pharming Group's earnings last quarter?

Pharming Group NV (OTCMKTS:PHGUF) released its quarterly earnings results on Thursday, March, 5th. The biotechnology company reported $0.05 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.01. Pharming Group had a negative trailing twelve-month return on equity of 6.01% and a negative net margin of 4.14%.

How do I buy shares of Pharming Group?

Shares of PHGUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/05/2015
• Today: 7/21/2025
• Next Earnings (Estimated): 7/31/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PHGUF
• Previous Symbol: OTC:PHGUF
• CIK: N/A
• Web: www.pharming.com
• Phone: (171) 524-7400
• Fax: 31-0-71-524-7445
• Employees: 382
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.84 million
• Net Margins: -4.14%
• Pretax Margin: -1.14%
• Return on Equity: -6.01%
• Return on Assets: -3.23%

Debt

• Debt-to-Equity Ratio: 0.51
• Current Ratio: 2.76
• Quick Ratio: 2.00

Sales & Book Value

• Annual Sales: $297.20 million
• Price / Sales: 2.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.33 per share
• Price / Book: 3.48

Miscellaneous

• Outstanding Shares: 671,070,000
• Free Float: N/A
• Market Cap: $771.73 million
• Optionable: Not Optionable
• Beta: 0.60